Bluejay Diagnostics Closes $8.5M Private Placement, Securing Up to $23.7M to Extend Runway
BJDX has more than doubled off its 52-week low of $1.623.
Summary
Bluejay Diagnostics announced the closing of its private placement, raising $8.5 million in gross proceeds upfront. The deal includes warrants that could bring in an additional $15.2 million if fully exercised, totaling up to $23.7 million. This follows the company's announcement on June 2nd regarding the terms of this private placement. The company's May 7th 10-Q reported only $3.7 million in cash and a going concern warning, stating cash would last only through Q3 2026 and $20 million was needed by 2027. This significant capital infusion is crucial for its survival. The proceeds are expected to extend the cash runway into Q1 2027, beyond the anticipated FDA submission, and potentially well beyond FDA approval if warrants are fully exercised. This directly addresses the severe liquidity concerns and going concern warning. The company intends to use proceeds for FDA approval-related activities and R&D.
At the time of this announcement, BJDX was trading at $4.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $1.62 to $16.68. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.